Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target

被引:22
|
作者
Sousa, Joao Andre [1 ]
Bernardes, Catarina [1 ]
Bernardo-Castro, Sara [1 ,2 ]
Lino, Miguel [3 ]
Albino, Ines [3 ]
Ferreira, Lino [2 ,3 ]
Bras, Jose [4 ]
Guerreiro, Rita [4 ]
Tabuas-Pereira, Miguel [1 ,2 ]
Baldeiras, Ines [2 ,5 ]
Santana, Isabel [1 ,2 ,5 ]
Sargento-Freitas, Joao [1 ,2 ,3 ,5 ]
机构
[1] Ctr Hosp & Univ Coimbra, Dept Neurol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[4] Van Andel Inst, Dept Neurodegenerat Sci, Grand Rapids, MI USA
[5] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
关键词
blood-brain barrier; nanomaterials; Alzheimer's disease; neurodegenerative diseases; amyloid clearance; genetic targeting; AMYLOID-BETA; MOUSE MODEL; NEUROVASCULAR DYSFUNCTION; DRUG-DELIVERY; THERAPEUTIC STRATEGIES; COGNITIVE IMPAIRMENT; P-GLYCOPROTEIN; CLEARANCE; RAGE; FLOW;
D O I
10.3389/fnagi.2023.1102809
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two unique central nervous system vasculature features that result in an intimate relationship between neurons, glia, and blood vessels. This leads to a significant pathophysiological overlap between neurodegenerative and cerebrovascular diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease whose pathogenesis is still to be unveiled but has mostly been explored under the light of the amyloid-cascade hypothesis. Either as a trigger, bystander, or consequence of neurodegeneration, vascular dysfunction is an early component of the pathological conundrum of AD. The anatomical and functional substrate of this neurovascular degeneration is the BBB, a dynamic and semi-permeable interface between blood and the central nervous system that has consistently been shown to be defective. Several molecular and genetic changes have been demonstrated to mediate vascular dysfunction and BBB disruption in AD. The isoform epsilon 4 of Apolipoprotein E is at the same time the strongest genetic risk factor for AD and a known promoter of BBB dysfunction. Low-density lipoprotein receptor-related protein 1 (LRP-1), P-glycoprotein, and receptor for advanced glycation end products (RAGE) are examples of BBB transporters implicated in its pathogenesis due to their role in the trafficking of amyloid-beta. This disease is currently devoid of strategies that change the natural course of this burdening illness. This unsuccess may partly be explained by our misunderstanding of the disease pathogenesis and our inability to develop drugs that are effectively delivered to the brain. BBB may represent a therapeutic opportunity as a target itself or as a therapeutic vehicle. In this review, we aim to explore the role of BBB in the pathogenesis of AD including the genetic background and detail how it can be targeted in future therapeutic research.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Transport of apolipoproteins E and J at the blood-brain barrier - Relevance to Alzheimer's disease
    Martel, CL
    Ghiso, J
    Frangione, B
    Zlokovic, BV
    STP PHARMA SCIENCES, 1997, 7 (01): : 28 - 36
  • [42] Alzheimer's disease drug development and the problem of the blood-brain barrier
    Pardridge, William A.
    ALZHEIMERS & DEMENTIA, 2009, 5 (05) : 427 - 432
  • [43] Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology
    Dong, Nana
    Ali-Khiavi, Payam
    Ghavamikia, Nima
    Pakmehr, Seyedabbas
    Sotoudegan, Farzaneh
    Hjazi, Ahmed
    Gargari, Morad Kohandel
    Gargari, Homa Kohandel
    Behnamrad, Parisa
    Rajabi, Mohammadreza
    Elhami, Anis
    Saffarfar, Hossein
    Nourizadeh, Mehrdad
    NEUROLOGICAL SCIENCES, 2024, : 1489 - 1507
  • [44] The blood brain barrier in Alzheimer's disease
    Chakraborty, A.
    de Wit, N. M.
    van der Flier, W. M.
    de Vries, H. E.
    VASCULAR PHARMACOLOGY, 2017, 89 : 12 - 18
  • [45] The blood-brain barrier as a treatment target for neurodegenerative disorders
    Rust, Ruslan
    Sagare, Abhay P.
    Zhang, Mingzi
    Zlokovic, Berislav V.
    Kisler, Kassandra
    EXPERT OPINION ON DRUG DELIVERY, 2025, 22 (05) : 673 - 692
  • [46] Xixin Decoction's novel mechanism for alleviating Alzheimer's disease cognitive dysfunction by modulating amyloid-β transport across the blood-brain barrier to reduce neuroinflammation
    Yang, Chaokai
    Zhao, Enlong
    Zhang, Hu
    Duan, Liqi
    Han, Xinyue
    Ding, Hongli
    Cheng, Yan
    Wang, Dengkun
    Lei, Xiaojing
    Diwu, Yongchang
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [47] Alzheimer's disease: A matter of blood-brain barrier dysfunction?
    Montagne, Axel
    Zhao, Zhen
    Zlokovic, Berislav V.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2017, 214 (11) : 3151 - 3169
  • [48] Immunotherapy and neuroimmunology in Alzheimer's disease: a perspective from the blood-brain barrier
    Banks, William A.
    IMMUNOTHERAPY, 2010, 2 (01) : 1 - 3
  • [49] Vascular Risk Factors and Alzheimer's Disease: Blood-Brain Barrier Disruption, Metabolic Syndromes, and Molecular Links
    He, Jin-Ting
    Zhao, Xin
    Xu, Lei
    Mao, Cui-Ying
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 73 (01) : 39 - 58
  • [50] Protecting P-glycoprotein at the blood-brain barrier from degradation in an Alzheimer's disease mouse model
    Ding, Yujie
    Zhong, Yu
    Baldeshwiler, Andrea
    Abner, Erin L.
    Bauer, Bjorn
    Hartz, Anika M. S.
    FLUIDS AND BARRIERS OF THE CNS, 2021, 18 (01)